Although clinical trials cannot yet be considered conclusive in humans, the glucagon-like peptide 1 (GLP1R) receptor agonist called exenatide improved motor function in patients with PD, and, when analyzing the brain effects of another GLP1R agonist called NLY01, it was suggested that the anti-inflammatory effects of these type of drugs could be mainly responsible for the improvements observed in the clinical trial with exenatide [116]. The gene discussed is GLP1R; the disease is Parkinson disease.